Introduction

• Robust Market Expansion: The Global Liquid Biopsy Market is poised for remarkable growth, with a projected valuation of approximately USD 7.25 billion in 2025, expected to surge to nearly USD 30.24 billion by 2035. This trajectory highlights the increasing adoption of non-invasive diagnostic technologies in oncology and personalized medicine.
• High Growth Momentum: The market is anticipated to register a strong compound annual growth rate (CAGR) of around 16.34% between 2025 and 2035, reflecting rising investments in advanced liquid biopsy platforms, technological innovations, and expanding applications across cancer detection, treatment monitoring, and early diagnostics.
• Strategic Industry Implications: The growing market underscores a shift toward precision healthcare solutions, encouraging collaborations between biotech companies, diagnostic labs, and healthcare providers to enhance patient outcomes, optimize treatment strategies, and improve early disease detection efficiency.

Porter’s Five Forces Analysis – Global Liquid Biopsy Market

1. Threat of New Entrants – Moderate:

• Entry barriers are moderate due to high capital investment and technological complexity.
• However, demand for non-invasive diagnostics and regulatory support attract new entrants.

2. Bargaining Power of Suppliers – Low to Moderate:

• Suppliers of reagents and sequencing tools have limited leverage due to global competition.
• Strategic partnerships and bulk procurement reduce supplier dependency.

3. Bargaining Power of Buyers – High:

• Buyers include hospitals, diagnostic labs, and research centers with multiple choices.
• High price sensitivity and demand for accuracy increase buyer influence.

4. Threat of Substitutes – Moderate to High:

• Alternatives include tissue biopsies and novel diagnostics like imaging or AI-based systems.
• Yet, the real-time, non-invasive nature of liquid biopsy offers strong differentiation.

5. Industry Rivalry – High:

• The sector is crowded with biotech giants, diagnostic innovators, and emerging startups.
• Intense R&D activity, IP battles, and global competition drive rivalry.

Market Segmentation – Global Liquid Biopsy Market

1. By Technology:
1.1 Next-Generation Sequencing (NGS)
1.2 Digital PCR (dPCR)
1.3 PCR-based Methods
1.4 Microarrays
1.5 CRISPR-based Diagnostics
2. By Biomarker Type:
2.1 Circulating Tumor DNA (ctDNA)
2.2 Circulating Tumor Cells (CTCs)
2.3 Exosomes & Extracellular Vesicles
2.4 Cell-Free RNA (cfRNA)
3. By Sample Type:
3.1 Blood
3.2 Urine
3.3 Saliva
3.4 Feces
4. By Application:
4.1 Early Cancer Detection
4.2 Treatment Monitoring
4.3 Recurrence Monitoring
4.4 Non-Cancer Applications
5. By End-User:
5.1 Hospitals & Laboratories
5.2 Research Institutes
5.3 Clinics & Diagnostic Centers
6. By Region:
6.1 North America
6.1.1 United States
6.2 Europe
6.2.1 Germany
6.2.2 United Kingdom
6.3 Asia Pacific
6.3.1 China
6.3.2 India
6.4 Latin America & Middle East & Africa

Key Players – Global Liquid Biopsy Market

• Guardant Health, Inc.
• Illumina, Inc.
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.
• Qiagen N.V.
• Personalis, Inc.
• Foundation Medicine, Inc.
• NeoGenomics Laboratories
• Biocept, Inc.
• Exosome Sciences Inc.